Men with localized prostate cancer requiring intermittent androgen deprivation therapy for
biochemical recurrence following radical therapy will be asked to participate in a phase 4
safety and efficacy clinical trial comparing 10 months versus 4 months of degarelix
(Firmagon®) therapy with the endpoint of prolonging the off treatment interval.